Regenxbio Inc Asset Resilience Ratio
Regenxbio Inc asset resilience ratio. Regenxbio Inc (RGNX) has an Asset Resilience Ratio of 17.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Regenxbio Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Regenxbio Inc (2015–2025)
Asset resilience ratio of Regenxbio Inc from 2015 to 2025. This chart shows how Regenxbio Inc's Asset Resilience Ratio has changed over time. Read Regenxbio Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Regenxbio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RGNX current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $69.03 Million | 17.85% |
| Total Liquid Assets | $69.03 Million | 17.85% |
Asset Resilience Insights
- Good Liquidity Position: Regenxbio Inc maintains a healthy 17.85% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Regenxbio Inc Industry Peers by Asset Resilience Ratio
Compare Regenxbio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Regenxbio Inc Asset Resilience Ratio by Year (2015–2025)
Regenxbio Inc asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Regenxbio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.18% | $195.60 Million | $453.03 Million | +5.16pp |
| 2024-12-31 | 38.02% | $177.16 Million | $465.99 Million | -3.92pp |
| 2023-12-31 | 41.94% | $240.74 Million | $573.97 Million | +9.82pp |
| 2022-12-31 | 32.13% | $267.69 Million | $833.27 Million | +22.05pp |
| 2021-12-31 | 10.08% | $112.23 Million | $1.11 Billion | -9.31pp |
| 2020-12-31 | 19.39% | $137.31 Million | $708.16 Million | -26.14pp |
| 2019-12-31 | 45.53% | $226.70 Million | $497.91 Million | +0.62pp |
| 2018-12-31 | 44.91% | $244.20 Million | $543.81 Million | -12.54pp |
| 2017-12-31 | 57.44% | $114.12 Million | $198.68 Million | +19.98pp |
| 2016-12-31 | 37.46% | $64.71 Million | $172.73 Million | +10.35pp |
| 2015-12-31 | 27.11% | $60.02 Million | $221.38 Million | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more